Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
Trial details
- Registry ID
- NCT05399641
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as SCY-078
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Ibrexafungerp for the Treatment of Complicated Vulvovaginal CandidiasisNCT05399641 | SCYX | Phase 3 | Completed | 2023-05-16Actual |
| Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal TreatmentNCT03059992 | SCYX | Phase 3 | Completed | 2023-08-25Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |